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Abstract: While intensive efforts have been made for the treatment of cancer, this disease 
is  still  the  second  leading  cause  of  death  in  many  countries.  Metastatic  breast  cancer,  
late-stage colon cancer, malignant melanoma, multiple myeloma, and other forms of cancer 
are still essentially incurable in most cases. Recent advances in genomic technologies have 
permitted the simultaneous evaluation of DNA sequence-based alterations together with 
copy  number  gains  and  losses.  The  requirement  for  a  multi-targeting  approach  is  the 
common  theme  that  emerges  from  these  studies.  Therefore,  the  combination  of  new 
targeted  biological  and  cytotoxic  agents  is  currently  under  investigation  in  multimodal 
treatment regimens. Similarly, a combinational principle is applied in traditional Chinese 
medicine, as formulas consist of several types of medicinal herbs or minerals, in which one 
represents the principal component, and the others serve as adjuvant ones that assist the 
effects,  or  facilitate  the  delivery,  of  the  principal  component.  In  Western  medicine, 
approximately  60  different  arsenic  preparations  have  been  developed  and  used  in 
pharmacological  history.  In  traditional  Chinese  medicines,  different  forms  of  mineral 
arsenicals (orpiment—As2S3, realgar—As4S4, and arsenolite—arsenic trioxide, As2O3) are 
used, and realgar alone is included in 22 oral remedies that are recognized by the Chinese 
Pharmacopeia Committee (2005). It is known that a significant portion of some forms of 
mineral arsenicals is poorly absorbed into the body, and would be unavailable to cause 
systemic  damage.  This  review  primary  focuses  on  the  application  of  arsenic  sulfide 
(realgar) for treatment of various forms of cancer in vitro and in vivo. 
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1. Introduction 
While intensive efforts have been made for the treatment of cancer, this disease is still the second 
leading cause of death in many countries. Nearly 10.9 million new cases were diagnosed in the year 
2005. In spite of enormous effort, the mortality rate due to cancer did not change in the past five to six 
decades [1]. Metastatic breast cancer, late-stage colon cancer, malignant melanoma, and other forms of 
cancer are still essentially incurable in most cases. The past quarter century of outstanding progress in 
fundamental cancer biology has not translated into even distantly comparable advances in the clinical 
practice [2]. The effectiveness of cancer therapy is limited by the rapid removal of anticancer agents 
from the circulation by metabolism or excretion, by the inability to access and penetrate the target 
cancer cells, or by nonspecific uptake by sensitive normal cells and tissues [3]. 
A strategy could be to associate anticancer agents with nanoparticles so as to overcome mechanisms 
of resistance and to increase the selectivity of such agents towards cancer cells, while reducing the 
drugs’ toxicity towards normal cells and issues. If designed properly, nanoparticles (defined usually as 
materials with a size < 100 nm) may act as drug vehicles that are able to target tumor tissues or cells, 
to  a  certain  extent,  while  protecting  the  agent  from  premature  activation  during  its  transport  [4]. 
Because their properties differ from those of their bulk counterparts, nanoparticles offer a range of 
potential applications in cancer treatment, especially in the targeting and imaging or cells or tissues. 
This review primary focuses on the application of arsenic sulfide (As4S4, realgar, REA) for the 
treatment of various forms of cancer in vitro and in vivo. 
2. Medicinal Use of Arsenic Compounds 
Several papers describing the effect of arsenic derived compounds for medicinal purposes have 
been published recently [5–8]. 
2.1. History 
Arsenic compounds had a long Janus-type interaction with humanity. On one hand, they have been 
extensively utilized, but on the other hand, their poisonous properties have caused misery and many 
deaths.  Because  of  their  significant  properties,  arsenic  compounds  have  been  used  as  therapeutic 
agents for more than 2400 years [5]. In early times of the East, a mixture of orpiment, slaked lime 
(CaO), and water was favored as a depilatory. Moreover, a paste of realgar was recommended by 
Hippocrates  for  treatment  of  ulcers.  Arsenic  compounds  have  also  been  used  to  treat  the  plague, 
malaria, and cancer. Arsenides and arsenic salts were key ingredients in antiseptics, antispasmodics, 
antiperiodics,  caustics,  cholagogues,  hematinics,  sedatives,  and  tonics.  Approximately  60  different 
arsenic preparations have been developed and distributed during the history [7].  
Among inorganic compounds of arsenic, Fowlers’ solution (potassium bicarbonate-based solution 
of arsenic oxide As2O3) was used in the treatment of asthma, chorea, eczema, pemphigus, pernicious Toxins 2010, 2  
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anemia, psoriasis, Hodgkin’s disease, and leukemia. However, in the early 20th century, this form of 
cancer management was supplanted by radiation therapy and cytotoxic chemotherapy [8].  
2.2. Arsenic oxide As2O3 (arsenolite, ATO) and tetraarsenic oxide As4O6 (TAO) 
In Chinese traditional medicine, ATO has been applied for more than 500 years. Pishang, or white 
arsenic, which essentially contained ATO, was used originally in the treatment of certain skin diseases 
and asthma, and to promote the healing of surgical wounds [9]. Based on the principle in Chinese 
traditional medicine of ―using a toxic agent against a toxic agent‖, in the early 1970s, a group of 
clinical researchers at Harbin Medical University began to treat some types of cancer with ATO. These 
initial treatments were followed by a careful clinical trial at the Shanghai Second Medical University, 
which documented remarkable clinical efficacy in patients with newly diagnosed and relapsed acute 
promyelocytic leukemia (APL) [8]. Patients were treated daily with 10 mg of intravenous ATO infused 
over two to three hours. This monotherapy produced complete remission in six (85.7%) of seven patients 
presenting with de novo APL [10]. The pivotal studies in China have been followed by investigations in 
the United States. The induction of complete remission with low doses ATO in APL patients has been 
confirmed  [11].  The  exhaustive  list  of  clinical  trials  employing  arsenic-based  cancer  drugs  in 
hematological malignancies and in solid tumors was published [6], while detailed overviews about the 
signal  transduction  pathways  and  the  transcription  factors  triggered  by  ATO  in  leukemic  cells  are 
reviewed  in  [12].  It  was  suggested  that  alteration  of  cellular  function  and  intracellular  signal 
transduction  pathway  modulations  by  arsenical  drugs  may  result  in  the  induction  of  apoptosis, 
inhibition  of  growth  and  angiogenesis,  and  the  promotion  of  differentiation  [7].  Recently,  the 
proteolytic degradation of the oncoprotein, PML-RARA, as a general strategy for the eradication of 
APL with ATO, due to the rapid clearing of leukemia initiating cells, was presented [13].  
In 2003, novel orally administrable angiogenesis inhibitors were introduced by a Korean-American 
team, and the ability of TAO to suppress several steps of the angiogenic process both in vitro and in 
vivo  was  documented  [14].  It  was  shown  that  this  agent  significantly  decreased  the  proliferation, 
migration,  invasion,  and  tube  formation  of  endothelial  cells  induced  by  the  angiogenic  factors.  In 
summary, TAO appears to be a novel antiangiogenic and antimetastatic chemical agent that can be orally 
administered [14].  
2.3. Arsenic sulfide As4S4 (realgar, REA) on scene 
The use of arsenic sulfide As4S4 (realgar, REA) for battling cancer, in spite of a long tradition of 
arsenic application for medicinal treatment, is seen only in a few countries. With the exception of 
China—where application of REA can be traced for a very long time—in vitro experiments were 
observed only in Korea [15], Singapore [16], and Slovakia [15,17]. 
2.4. Chinese traditional medicine 
Realgar (Xiong Huang) is listed in the modern Chinese Pharmacopoeia and is suggested to be made 
into pills or powders for use, and is taken at a dosage of 150–300 mg each time, with long-term 
administration being avoided. The discovery that indigo (a purple dye obtained from certain plants) Toxins 2010, 2  
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has a component, indirubin, which is clinically effective for leukemia, was made in the early 1960s, 
when researchers at the Institute of Hematology, Chinese Academy of Sciences (Beijing) noted that an 
herbal formula prescribed by Chinese doctors appeared to be producing good results in many APL 
patients. A modified version of the traditional formula, which includes both indigo and REA with 
Salvia miltiorrhiza, and tanshinone IIA as major active ingredients, was developed at this Institute [18].  
The fundamental problem in REA application is its low solubility. REA in Niuhuang Jiedu Pian, a 
common preparation for the common cold, has a low solubility in water, and only 4% is bioavailable 
in  physiological gastric juice  or  intestinal fluid  [19]. The average  total  arsenic concentration in  a 
Niuhuang Jiedu Pian is approximately 7 ±  1% (i.e., 70,000 ppm), corresponding to 28 mg of arsenic 
per pill; of this only 1 mg of arsenic finds its way into the blood stream, and 40% of this absorbed 
arsenic (0.4 mg) is excreted in urine [19]. To overcome the low solubility and poor bioavailability, 
realgar  particles  have  been  prepared  and  applied  in  nanosized  dimensions  (see  coming  text).  The 
average  rate  of  DNA  damage  in  the  total  body  is  represented  by  the  urinary  level  of  8-OH-dG  
(8-hydroxy-2′-deoxyguanosine), and is the most accepted biomarker of oxidative DNA damage. A 
recent study [20] reveals that arsenite caused significantly higher urinary 8-OH-dG levels than both 
realgar and orpiment on exposure to the same amount of compound. As the effectiveness of subsequent 
DNA repair determines the outcomes of treatment, significant differences may exist between species, as 
well as between individuals, due to inter-individual variation in DNA damage repair [21]. 
Both efficacy and side effects need to be considered in evaluating a drug. As described in previous 
paragraphs, ATO is an effective drug in patients with APL, despite the occurrence of some severe side 
effects. REA is almost insoluble in aqueous solution at neutral and slightly acidic conditions, and 
consequently will exhibit much less toxicity and better tolerance, in comparison with patients treated 
with ATO. NMR-based metabolomic analysis of urine, serum, and aqueous extracts of the liver tissue 
of  Wistar  rats  fed  with  REA  highlighted  a  number  of  complex  disturbances  in  the  endogenous 
metabolite profiles. Altered transmethylation, hypoglycemia, hyperlipoidemia, suspected reduction of 
intestinal  microflora,  and  oxidative  injury  of  the  liver  are  related  to  realgar  induced  biochemical 
pathway perturbation [22]. It will be shown that REA is also effective for patients who relapsed after 
treatment with ATRA or chemotherapy. Since smaller amounts of realgar are needed for the induction 
of  differentiation,  than  for  apoptosis,  the  differentiation  therapy  deserves  to  be  developed  as  a 
complement to other current therapies [23].  
2.5. Solid state properties 
Realgar is a red compound that exists in several crystalline forms. At least two polymorphs of As4S4 
(sometimes referred as As2S2 or AsS) have been reported to date. The room temperature stable α-As4S4 
phase  is  structurally  identical  to  mineral  realgar  [24].  A  high-temperature  phase,  β-As4S4  can  be 
obtained by heating realgar above 260 °C. The β-phase can also be obtained by high-energy milling 
[25,26]. The β-phase is stable and slowly reconverts to the α-phase upon cooling. Upon exposure to 
visible light, both α- and β-phase transform from red materials into bright yellow pararealgar [27–30]. 
Both As4S4 phases consist of covalently bonded As4S4 cage-like molecules that have different crystal 
structures. The molecules are held together by weak van der Waals interactions [29]. Recently, the 
reaction mechanism underlying the photoinduced linkage isomerization of discrete As4S4 molecules in Toxins 2010, 2  
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realgar to its pararealgar form was observed [31]. Because of the fact that arsenic occurs naturally in 
many minerals and in groundwater in contact with geologic formations containing a high content of 
arsenic, more than 20 prokaryotes utilize arsenic as a terminal electron acceptor for energy generation 
that  goes  beyond  the  commonly  used  redox  mechanisms  of  detoxification  [32].  Among  these 
organisms, a distinct position is held by YeAs, which produces a biogenic mineral, -realgar [33]. 
Recently,  the  production  of  extracellular  networks  of  filamentous  arsenic-sulfide  nanotubes  by 
Shewanella  sp.  strain  HN-41  was  discovered  [34].  The  formed  nanotubes  are  initially  amorphous 
As2S3 that evolve with increasing time toward realgar and duranusite (AS4S). Upon maturation, the 
arsenic  sulfide  nanotubes  behaved  as  metals  and  semiconductors  in  terms  of  their  electrical  and 
photoconductive properties, respectively.  
2.6. Contemporary efforts 
A pilot report from the Beijing University Institute of Hematology and the People’s Hospital group 
dealt  with  the  treatment  of  APL  patients  with  REA  that  appeared  in  the  blood  [35].  Moderately 
purified REA was mixed with an equal amount (w/w) of ground Semen platycladi, as an excipient, and 
was  put  into  capsules  containing  250  mg  of  As4S4.  This  dosage  was  selected  on  the  basis  of  a  
dose-escalation trial and animal studies. In this small study, a group of volunteer patients showed that 
escalation  to  a  single  dose  of  60  mg/kg  REA  was  well  tolerated  [36].  Hematologically  complete 
remission (CR) was achieved in all patients with newly diagnosed APL, as well as in those with 
hematological relapse. Of 16 patients with newly diagnosed disease, and available cytogenetic and 
molecular analysis, 14 had cytogenetic and molecular CR. Treatment with well tolerated REA had 
only moderate side effects. Degeneration or apoptosis of APL promyelocytes was observed during 
REA therapy. Most urinary arsenic excretion occurred within the first 24 hours, and both blood and 
urine arsenic levels declined after discontinuation of REA. The results showed, for the first time, that 
REA treatment alone is highly effective and safe in both remission induction and maintenance therapy 
in patients with APL, regardless of disease stage [35]. Two years later, the first author of the described 
work has been granted a patent in the United States [37]. 
2.7. Mechanism of REA effect 
Treatment  of  promyelocytic  NB4  or  T-leukemia  CEM  cells  with  REA  induced  some  of  the 
morphological  features  of  apoptotic  cells.  The  expression  of  APO  2.7,  which  is  located  at  the 
membrane of mitochondria, was upregulated [38]. An assessment of the sensitivity of NB4 and K562 
cells to REA treatment revealed a low sensitivity of K562 cells, due to high expression of Bcl-x(L), 
which provides resistance to REA treatment. The reversion of resistance is achieved by transfecting 
bcl-x(L) antisense RNA vector; cells subsequently become sensitive to realgar at clinically acceptable 
concentrations [39]. The expression profile analysis of NB4 cells treated with REA using 1K chip 
revealed  the  upregulation  of  nine  genes  and  the  downregulation  of  37  genes  [40].  The  most 
pronounced effect of REA in NB4 cells—growth suppression and apoptosis—may by associated with 
induced reorganization of PML oncogenic domains. These domains are involved in transcriptional 
regulation and other different cellular functions [41]. The upregulation of proteasome PSMC2 and 
PSMD1 proteins can contribute to the degradation of fusion protein PML/RARa and to the increase of Toxins 2010, 2  
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Hsp90. These changes are consistent with stress-related cell responses [42], or with the facilitation of 
interactions  between  abnormal  protein  and  components  of  the  proteasomal  pathway.  Examples  of 
genes with decreased expression are as follow: MERTK, which encodes for a c-mer tyrosine kinase 
widely expressed in monocytes and macrophages, a regulator of G protein signaling 2 (RGS2) that 
belongs to a group of G0/G1 switch regulatory genes, and which is expressed in leukemia cells, with 
the exception of CML in the chronic phase and normal hematopoietic cells, genes that encode several 
ribosomal  proteins,  protein-tyrosine  phosphatase  4A,  which,  as  a  downstream  effector  of  p53  is 
involved in cell cycle regulation [43], and others. 
In  2004,  a  study  of  the  combined  effects  of  REA  and  imatinib  on  CML  cells  and  BCR-ABL 
oncoprotein was published [44]. Analysis of cell proliferation and clonogenic ability showed that REA 
and imatinib exerted synergistic effects on both K562 cells and on fresh CML cells. Both drugs under 
study also exhibited a synergistic effect in targeting the BCR-ABL protein. While REA triggered its 
degradation  and  imatinib  inhibited  its  tyrosine  kinase  activity,  their  combined  use  led  to  lower 
enzymatic  activity  levels  of  BCR-ABL.  This  combination  represents  a  new  model  of  synergistic 
targeting at the molecular level and might be a promising approach for improving response rates and 
for resistance prevention. The expression profile of human multiple myeloma RPMI8226 cells treated 
with REA identifies the upregulation of 54 and the downregulation of 60 genes [45]. Upregulated 
genes are associated with a variety of cell functions, such as the regulation of apoptosis, cell-cell 
signaling, cell growth, and cell homeostasis. These genes include ones that code for the monocyte 
chemotactic  protein  MCP1,  the  macrophage  inflammatory  protein  MIP-1,  several  TNF-induced 
proteins, and the binding protein for insulin-like growth factor IGFBP4, which is involved in the 
systematic and local regulation of IGF activity, along with the B-cell translocation gene BTG1, which 
negatively  regulates  cell  proliferation.  When  comparing  the  extent  of  gene  expression  changes  in 
ATO-treated RPMI8226 cells, it was found that 121 genes were upregulated and 152 down-regulated, 
most significantly thioredoxin-interacting protein TXNIP and activin receptor-like kinase ALK1 [46]. 
Results suggest that REA and ATO affect different set of genes. The additional differences in the 
sensitivity of cells to REA treatment may originate from differences in the tissue phenotype that the 
cells are derived from, because proliferation of normal human fibroblast Hs-68 cells was only slightly 
influenced,  while  high  cytotoxicity  in  HaCaT  immortalized  human  epidermal  keratinocytes  was 
observed [47]. 
CD11b expression and the NBT test confirmed that REA-induced differentiation of HL-60 cells is 
preceded with marked changes in ROS and catalase activity, and with small changes in superoxide 
dismutase  activity  and  in  levels  of  the  reduced  form  of  glutathione  [48].  The  effect  of  REA 
nanoparticles on the differentiation of HL-60 cells was synergized, enhanced, and suppressed by the 
inhibition  of  p38  MAPK,  JNK,  and  ERK  pathways,  respectively  [49].  The  analysis  of  human 
histocytic  lymphoma  U937  cell  death,  induced  by  REA  powder,  revealed  that  the  time-  and 
concentration-dependent induction of apoptosis begins to decrease with an enhanced necrotic cell ratio 
at  high  REA  concentrations.  The  use  of  a  panel  of  protein  kinase  inhibitors  demonstrates  the 
involvement of the PI3-K/Akt signaling pathway in the downregulation of SIRT1 deacetylase activity, 
the subsequent activation of p53, and apoptosis induction [50]. As SIRT1 deacetylates the DNA repair 
factor  Ku70,  causing  it  to  sequester  the  proapoptotic  factor  Bax  away  from  mitochondria, SIRT1 
inhibition can sensitize cells toward stress-induced apoptotic cell death [51]. Similar enhancement of Toxins 2010, 2  
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the phosphoacetylation of the p53 paralog, p73, was observed in NB4 and K562 cells that were treated 
with a combination of MEK inhibitor and ATO, which promotes a p300-mediated acetylation and the 
p73-induced upregulation of p21 and Bax [52].  
In paper [23], a trial has been described to compare the effect of REA and ATO on HL-60 cell 
differentiation, a leukemic cell line that is blocked at the level of promyelocytic differentiation [53]. 
The  differentiation  is  accompanied  by  changes  in  the  expression  of  surface  antigens  and  in  the 
acquisition  of  a  number  of  functions  indicative  of  cell  differentiation  into  granulocyte-like  or 
monocyte or macrophage-like cells [54]. ATO has been reported to induce granulocytic differentiation 
in  HL-60  cells  [55].  Although  REA  is  similar  to  ATO  in  inducing  HL-60  cell  differentiation  at  
sub-micromolarity, the differentiation pathways are different. As shown in paper [56], the involvement 
of  Ser/Thr  protein  phosphatases  in  the  differentiation  induced  by  REA  takes  a  place.  The  total 
activities of PP1 (serine/threonine protein phosphatase type 1) and type 2A (PP 2A) are elevated with 
increasing REA concentration (in the range of 0–2.0 μM), while the differentiation extent, as indicated 
by the NBT reduction assay, peaked at 0.75 μM of REA. On the other hand, it was found that the 
inhibitors  of  PP1,  PP2a,  and  PP2B  (cyclosporine  A  and  FK  506)  did  not  have  any  effect  on  
ATO-induced differentiation in HL-60 cells [57]. 
These  results  clearly  indicate  that  realgar  As4S4  is  different  from  arsenic  oxide  As2O3  in  the 
differentiation pathway and molecular mechanism.  
2.8. Nanomaterials for cancer treatment: realgar case 
Modification of water insoluble drugs (like REA) into ultra-fine particles with large surface areas is 
considered to be an efficient approach for improving bioavailability, and is practically important in the 
pharmaceutical industry. The application of micronization, if applied in a proper way, can lead to mean 
particle sizes of approximately 3–5 μm. However, many of the new drugs show such a low solubility 
that even micronization does not lead to a sufficient increase in bioavailability after oral administration 
[58].  Thus,  by  reducing  particle  sizes  from  micrometers  to  nanometers  (nanonization),  and  thus, 
increasing surface area, one or more order(s) of magnitude increase in dissolution rate can be achieved 
[58–60].  Tumor  vasculature  is  highly  abnormal,  proliferative,  activated,  and  tortuous;  it  presents 
increased permeability and gaps, with pores between 350 and 800 nm in diameter, and a cutoff around 
400 nm [61]. Thus preparation of nanoparticles to be 100–200 nm in diameter by any nanosizing 
technique gives a good predisposition for nanodrug penetration into a tumor body. While the reduction 
of particle sizes has been employed in the pharmaceutical industry for several decades, recent advances 
in milling technology have enabled the production of such nanoparticles in a reproducible manner. 
Nanocrystalline dispersions are prepared using the media milling processes [62,63]. The media milling 
process readily fractures micron-sized drug crystals into homogeneous nanoparticle dispersions. 
There are a small amount of papers dealing with the application of nanorealgar (NREA) in cancer 
treatment. In 2001, a paper has been published which deals with the size effects of realgar particles on 
apoptosis in a human umbilical vein endothelial cell line ECV-304 [64]. Four different suspensions of 
NREA particles, with diameters in the range of 100–500 nm, which contained equivalent doses, were 
investigated to determine their size effects. Remarkable cytotoxic effects and induction of apoptosis 
confirmed by cell morphology, flow cytometry analysis, and DNA ladder presence, was achieved by Toxins 2010, 2  
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exposure of cells to realgar particles of diameters of 100 and 150 nm, whereas the treatment of cells 
with particles of a diameter of 200 and 500 nm had only slight effects on cell viability. Authors 
suggested that the inhibition of angiogenesis may account for the therapeutic effect of nanosized REA 
particles. The concentration-dependent decrease of cancer cell line viability was observed, and the 
most sensitive cells for nanosized REA are HL-60 and K562 cells, followed by the more resistant 
multiple myeloma ARH 77 and U-266 cell lines [17]. 
In paper [65], the effect of long-term milling (six hours) of REA on induction of cytotoxicity in 
human promyelocytic leukemia HL-60 cells has been studied. Such a milling mode usually brings 
aggregation and agglomeration effects in solids [26]. As a post-milling procedure, authors prepared a 
solid dispersion using polyethylene glycol (PEG 6000) as the carrier. Based on published SEM and 
TEM images, one cannot be strongly convinced about the presence of nanoparticles, in spite of the 
author’s  statement  of  particle  size  (200  nm).  The  described  milling  performance  needs  a  more 
thorough, critical treatment because such a milling mode can bring contamination into realgar, as a 
consequence of wear from the milling media. In spite of this drawback, the paper brings new insights. 
It was found that treatment with NREA resulted in considerably lower cell viability compared with 
that of raw realgar particles. On the other hand, treatment with NREA promoted the generation of 
reactive oxygen species, inhibition of catalase activity, accompanied by lipid peroxidation and protein 
oxidation, and the loss of protein free thiols, whereas such events were not observed in HL-60 cells 
exposed to raw (higher diameter) REA particles. Another paper [66] shows that both NREA and raw 
REA particles reduced membrane fluidity in HL-60 cells, while enhancements in LDH leakage and 
membrane  lipid  peroxidation  were  observed  in  nanoparticle  REA-treated  cells,  in  comparison  to 
control or raw REA-treated cells. In addition, nanoparticle REA significantly decreased cell viability 
and produced DNA ladder formation, along with the appearance of cells at the sub-G1 phase, whereas 
raw REA particles failed to produce characteristic apoptotic events. Treatment of HL-60 cells with 
REA powder filtered through a 0.22 m filter membrane revealed that membrane lipid peroxidation 
was achieved at the lowest concentration of REA and LDH leakage, and DNA fragmentation occurred 
at higher concentrations used. Analysis of atomic force microscope images confirmed the existence of 
a  disorganized  membrane  surface  consisting  of  protruding  protein  clusters  and  confirmed  the 
membrane toxic effect of REA in HL-60 cells [67]. 
The technique of cryo-milling has been applied for the first time at the National University of 
Singapore  for  the  preparation  of  NREA  samples  to  evaluate  their  in  vitro  activity  and  in  vivo 
bioavailability [16]. The particle size of NREA ground in the presence of polyvinylpyrrolidone (PVP) 
or sodium dodecyl sulphate (SDS) was in the range from 176 to 243 nm, and was measured by means 
of a Zetasizer, while TEM images revealed a size of about 50 nm. The plausible explanation is that the 
particles observed by TEM were the individual realgar particles, whilst the particles apparent to the 
Zetasizer  were  the  realgar  particles  with  PVP  or  SDS  coating(s),  or  both.  The  cytotoxic  and  
anti-proliferative effects of such NREA particles in human ovarian CI80-13S, OVCAR, OVCAR-3, 
and cervical HeLa cancer cell lines were observed. CI80-13S are most sensitive to the NREA with IC50 
values of less than 1 μM, whereas the other cancer cell lines had IC50 values in a range of 2–4 μM 
NREA. The cytotoxic activity of the NREA particles to these human gynecological cell lines was 
comparable  to  ATO  cytotoxic  effects  and  was  due  to  apoptosis  induction.  Bioavailability 
investigations revealed a remarkable increase in the urinary recovery of arsenic in rats after a single Toxins 2010, 2  
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oral administration of the NREA particle suspension. The administered dose of arsenic recovered in 
urine from the NREA preparation in presence of PVP or SDS, or both, ranged from 59–79%, whereas 
the original REA powder gave a urinary recovery of only 25%. The improvement in bioavailability can 
be attributed to the realgar particles’ size reduction. 
It is well known that cysteine-dependent aspartame specific proteases (caspases) are an important 
mediator  of  signal  transduction  in  apoptosis.  Both  induction  of  apoptosis  and  prevention  of 
angiogenesis enhance the anticancer effect of the transferal delivery of REA nanoparticles against 
mouse  melanoma  B16  cells.  In  this  treatment,  there  seems  to  be  no  apparent  in  vivo  toxic 
manifestation, as evaluated in terms of body weight changes, feeding behavior, skin irritation, and liver 
injury [68]. REA nanoparticle-induced apoptosis in U937 cells was partially prevented by inhibitors of 
caspase-3, -8, and -9 [69]. While inhibitors of ERK and p38 kinases failed to block cell death, the 
inhibitor  of  JNK  significantly  inhibits  REA-induced  apoptosis.  The  REA-induced  increase  of  the 
Bax/Bcl-2  ratio  and  the  phosphorylation  of  JNK  are  involved  in  U937  apoptosis.  Similarly,  the 
proliferation and viability of CML cell line K562 is affected by micromolar concentrations of REA. 
The REA treatment decreases Bcr-Abl protein content, although the mRNA level of the bcr-abl fusion 
gene does not change. Consequently the PTK activity of c-Abl and Bcr-Abl was decreased in a time- 
and concentration-dependent manner. Compared with CML Ph+ leukemia cells, Ph− mononuclear 
cells were less sensitive to REA treatment at all concentrations tested. When targeting the Bcr-Abl, the 
crucial factor of CML pathogenesis and  the higher sensitivity of Ph+ cells to apoptosis induction 
suggests the therapeutic potential of REA for CML patients [70].  
3. Conclusion 
In traditional Chinese medicine, there is well established multicomponent characters for remedies. 
The combination of arsenicals with natural compounds can modify unpleasant side effects, such as 
cardiotoxicity or genotoxicity in normal cells [71,72] or enhance the cytotoxic effect [18]. On the other 
hand, the effective surface modification of insoluble arsenic particles with ligand targeted to tumor 
cells represents a promising tool for the enhanced hit-and-kill antitumor effect of future nanomedicine 
approaches to cancer patient treatment. 
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